Neuronetics Eyes Recovery Through TMS Sales and Psychedelic Clinics
Neuronetics has struggled with difficult market conditions, less competitive TMS technology, and limited innovation. Better demand and a more flexible NeuroStar sales model could help revive system sales. The company's Greenbrook clinic network may offer long-term potential in psychedelic therapies, though treatment economics and commercialization timelines remain uncertain.
Neuronetics, ticker STIM, has faced a tough stretch marked by weak market conditions, less capable transcranial magnetic stimulation offerings, and slow product development. The article, published in October 2026 by Richard Durant, notes that demand has improved and that a revised NeuroStar commercial approach—including outright purchases and leasing—might revive system sales.
The company’s Greenbrook clinic network is also framed as a possible long-term route into psychedelic treatment infrastructure. However, the piece cautions that competitive standing, execution, treatment economics, and commercialization schedules remain unresolved. Durant’s disclosed position is in CMPS, not STIM, and he favors waiting for clearer TMS sales momentum or a cheaper valuation.
Count words. First para: Neuronetics(1), ticker2, STIM3, has4, faced5, a6, tough7, stretch8, marked9, by10, weak11, market12, conditions13, less14, capable15, transcranial16, magnetic17, stimulation18, offerings19, and20, slow21, product22, development23. The24 article25, published26 in27 October28 2026? "October 2026" maybe two? published in October 2026 by Richard Durant, notes that demand has improved and that a revised NeuroStar commercial approach—including outright purchases and leasing—might revive system sales. Count: The24 article25, published26 in27 October28 2026? If "2026" 29, by30 Richard31 Durant32, notes33 that34 demand35 has36 improved37 and38 that39 a40 revised41 NeuroStar42 commercial43 approach44
1 paragraph under 90 words measured analysis possible impact on society — who affected and how, framed could/may, never fact, no political advocacy. Need mention patients with depression? TMS used for depression? Source doesn't explicitly say depression. It says TMS technology, NeuroStar, Greenbrook clinics, psychedelic therapies. We can infer? Need drawn? Context can analyze possible impact on society. We can mention patients seeking non-drug or psychedelic-assisted mental health treatments, clinicians, investors. But source doesn't specify mental health? TMS and psychedelic clinics imply mental health. But "psychedelic therapies" likely mental health. We can say "people seeking treatment through TMS or psychedelic-assisted care" maybe. Who affected: patients, providers, investors, employers? Impact: if sales model improves, access to TMS systems could expand; if Greenbrook network advances psychedelic therapies, patients may gain options, but uncertain economics/timelines may delay a